Contemporary Pediatrics week in review: October 26-30, 2026

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, October 26 to Friday, October 30, 2026) and click each link to read and watch anything you may have missed.

4 societies tie girls' and women's heart health to female life stages

The American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine jointly released a "Female Life Stage" framework, published in Circulation, that ties cardiovascular prevention to hormonal transitions beginning around menarche. The framework divides female life into 4 stages—perimenarche (roughly ages 8-15), ovarian cycling (15-44), perimenopause (45-51), and postmenopause (51 and older)—and urges clinicians to evaluate cardiovascular, hormonal, and emotional health together rather than in isolation. It flags menstrual irregularities as a potential female-specific vital sign tied to cardiometabolic risk, including polycystic ovary syndrome (now also called polyendocrine metabolic ovarian syndrome), and designates pregnancy complications such as preeclampsia, gestational diabetes, and preterm birth as female-specific risk enhancers.

Cardiovascular disease kills more than 400,000 US women annually, more than breast cancer, lung cancer, and chronic lung disease combined, yet only 41% of women name it as their top health threat. The societies note that progress against cardiovascular mortality in women has stalled over the past 2 decades, and the AHA projects hypertension prevalence among women 20 and older could climb from about 49% in 2020 to 59% by 2050 if current trends hold. Much of the guidance is framed in hedged language—menstrual changes "may" signal risk, and pregnancy "can" unmask it—reflecting that the document is a presidential advisory rather than a randomized trial.

Self-harm risk peaks before ADHD medication initiation, study finds

A multinational self-controlled case series published in BMJ Mental Health, led by researchers at Aston University with collaborators across the UK, Hong Kong, New Zealand, South Korea, and Taiwan, analyzed more than 460,000 people who started ADHD medication and had a self-harm record between 2001 and 2020. The pooled, adjusted incidence rate ratio for self-harm was highest in the 90 days before medication initiation (2.58), fell to 1.78 in the first 90 days of treatment, and dropped further to 1.27—still above baseline—during ongoing treatment. The pre-treatment peak showed up consistently across all 5 health care systems studied.

The authors say the pattern argues against medication itself as the main driver of self-harm risk, and instead point to worsening symptoms before diagnosis and treatment as the likely explanation. They recommend close monitoring of patients around the time medication is started, particularly those whose symptoms are escalating. The article does not report absolute risk figures alongside the relative rate ratios, and the authors' causal interpretation is their own reading of an observational design rather than a directly tested mechanism.

25-valent pneumococcal vaccine hits all serotypes in infant trial

Pfizer presented phase 2 data at IDWeek 2026 on 25vPnC, an investigational 25-valent pneumococcal conjugate vaccine that adds 5 serotypes to the 20 already covered by Prevnar 20. In healthy infants given 4 doses around 2, 4, 6, and 12 to 15 months, the vaccine elicited immune responses against all 25 serotypes after the third and fourth doses, including the 5 serotypes not found in Prevnar 20, with local and systemic reactions balanced against the licensed comparator. Pfizer estimates the 25 serotypes account for roughly 84% of invasive pneumococcal disease in US children under 5, with the added serotypes representing about 30% more pediatric cases than Prevnar 20 covers.

The company did not disclose the phase 2 sample size, and the 5 newly added serotypes have no established correlate of protection in infants, meaning the immunogenicity data alone cannot confirm the vaccine will reduce disease incidence. Three phase 3 studies enrolling up to 6,830 participants are underway to test that question, and current vaccination recommendations are unchanged pending FDA review and ACIP deliberation.

Zilurgisertib reduces HO volume in children aged 6 to 11 with FOP

Mirum Pharmaceuticals reported topline results from PROGRESS Cohort 2, a phase 2 trial of zilurgisertib (Atebrioz), an oral ALK2 inhibitor already FDA-approved for patients 12 and older with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes muscle, tendon, and ligament tissue to progressively turn to bone. Among 25 children aged 6 to 11 randomized to the drug or placebo for 24 weeks, total heterotopic ossification (HO) volume shrank by a mean of 8.09 cm³ with zilurgisertib versus growing by 9.14 cm³ with placebo, and no new HO lesions developed in the treatment group versus 1 in the placebo group. No new safety signals, discontinuations, or growth plate closures emerged.

The cohort is small, the variability within each arm was wide, and the reported P value (.003) is nominal rather than confirmatory. A functional impairment scale (CAJIS) improved by less than a point more with zilurgisertib than placebo over 24 weeks, a difference the article notes may be too small to distinguish from the scale's natural year-over-year drift. The results come from a company announcement rather than a peer-reviewed publication, and Mirum plans to seek approval for this younger age group in the first half of 2027.

Brief evening screen time did not suppress melatonin in toddlers

A preregistered crossover study in Pediatrics Open Science, led by researchers at Ruhr University Bochum, had 32 toddlers aged 15 to 24 months watch 15 minutes of a children's show on a tablet or have a picture book read to them on 2 separate evenings before bedtime, then measured salivary melatonin and overnight sleep with an ankle actigraph. Melatonin rose significantly from baseline in both conditions, with no significant difference in melatonin levels or sleep duration, sleep onset latency, or sleep activity between tablet and book nights, even though a light sensor confirmed the tablet exposed children to more melanopic light than the book.

The researchers said they would not assume blue light delayed melatonin release in this setup, though screens could still affect sleep through other pathways, such as stimulating content. They caution the single 15-minute exposure may have been too brief to suppress melatonin the way longer lab-based light exposures have, and the study tested only 1 night per condition with notable variability between children, so it does not address habitual or longer screen use. The World Health Organization recommends no screen exposure before age 2, and the findings do not change that guidance.